

## The Interplay between Chagas Disease and Cardiovascular Disorders: A Comprehensive Review

Donaldo Emiliano Silva López<sup>1\*</sup>, Sussan Irlanda Méndez Ynostroza<sup>2</sup>, Claudia Paola Contreras Sáenz<sup>3</sup>, María Elisa González Robles<sup>4</sup>, Paola Daniela Aguirre Moreno<sup>5</sup>, José Pablo Adoño Marroquín<sup>6</sup>

<sup>1,2,3,5</sup>Hospital Centenario Miguel Hidalgo. Secretaria de salud. Aguascalientes, Aguascalientes, México.

<sup>4,6</sup>Hospital Civil de Guadalajara. Secretaria de salud. Guadalajara, Jalisco, México

### ABSTRACT

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a neglected tropical disease prevalent in Latin America. While traditionally known for its acute and chronic manifestations, recent research has shed light on its association with cardiovascular disorders. This review aims to explore the intricate relationship between Chagas disease and cardiovascular diseases, including cardiomyopathy, arrhythmias, and thromboembolic events. We delve into the epidemiology, pathophysiology, clinical manifestations, diagnostic challenges, and management strategies of these coexisting conditions. Additionally, we discuss the impact of Chagas disease on the cardiovascular system in the context of global health and highlight the importance of integrated care approaches for affected individuals.

**KEYWORDS:** Chagas, disease, protozan, cardiovascular.

### ARTICLE DETAILS

**Published On:**  
**18 April 2024**

**Available on:**  
**<https://ijmscr.org/>**

### INTRODUCTION

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a significant public health concern in Latin America, affecting approximately 6-7 million people worldwide. While traditionally recognized for its acute and chronic phases characterized by systemic manifestations, recent research has increasingly implicated Chagas disease in the development of cardiovascular disorders. This evolving understanding has challenged the traditional view of Chagas disease as solely a tropical disease, highlighting its relevance in the context of global cardiovascular health.<sup>1,2</sup>

The cardiovascular complications of Chagas disease are diverse and can manifest as myocarditis, dilated cardiomyopathy, arrhythmias, thromboembolic events, and even sudden cardiac death. The pathophysiology of Chagas-related cardiovascular complications is multifactorial, involving parasite-induced myocardial damage, inflammatory responses, autonomic dysfunction, and microvascular abnormalities. The chronic inflammatory state triggered by *T. cruzi* infection plays a pivotal role in the development and progression of these cardiovascular manifestations.<sup>1,2</sup>

Despite the growing recognition of the cardiovascular impact of Chagas disease, diagnosing and managing these conditions present significant challenges. The overlap of symptoms between Chagas-related cardiomyopathy and other cardiovascular diseases, coupled with limited access to healthcare in endemic regions, contributes to underdiagnosis and undertreatment. Additionally, the lack of specific biomarkers for Chagas-related cardiovascular complications further complicates early detection and management.<sup>1,2</sup>

Given the complex interplay between Chagas disease and cardiovascular disorders, a multidisciplinary approach involving cardiologists, infectious disease specialists, and primary care providers is essential for optimal patient care. Integrated care strategies that address both the parasitic infection and the associated cardiovascular complications are crucial for improving outcomes and reducing the burden of Chagas disease on affected individuals and healthcare systems. This review aims to provide a comprehensive overview of the relationship between Chagas disease and cardiovascular disorders, emphasizing the need for continued research and global collaboration in combating this dual burden of disease.<sup>3,4</sup>

### EPIDEMIOLOGY

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, remains a significant public health challenge in Latin America and other endemic regions, affecting an estimated 6-7 million people worldwide. The disease is primarily transmitted through the feces of infected triatomine bugs, known as "kissing bugs," which are endemic to rural areas of Latin America. However, other modes of transmission, such as congenital transmission, blood transfusion, organ transplantation, and oral transmission through contaminated food or drink, have been reported, highlighting the complex epidemiology of the disease.<sup>3,4</sup>

The epidemiology of Chagas disease is characterized by its wide geographic distribution, with endemic regions spanning from the southern United States to Argentina. The burden of the disease is particularly high in countries such as Bolivia, Paraguay, and Honduras, where prevalence rates can exceed 10% in some regions. The distribution of Chagas disease is closely linked to socioeconomic factors, with poverty, inadequate housing, and limited access to healthcare contributing to the persistence of the disease in endemic areas.<sup>5,6</sup>

One of the hallmark features of Chagas disease is its chronic nature, with individuals often remaining asymptomatic for years or even decades after initial infection. This chronic phase is characterized by the development of cardiac and gastrointestinal complications, which are the leading causes of morbidity and mortality in patients with Chagas disease. Cardiovascular complications, including dilated cardiomyopathy, arrhythmias, and thromboembolic events, are particularly common and can have devastating consequences for affected individuals.<sup>5,6</sup>

The relationship between Chagas disease and cardiovascular diseases is complex and multifactorial. The chronic inflammatory state induced by *T. cruzi* infection plays a key role in the pathogenesis of Chagas-related cardiomyopathy, leading to progressive myocardial damage and dysfunction. Additionally, autonomic dysfunction, microvascular abnormalities, and the presence of parasite antigens in cardiac tissue further contribute to the development of cardiovascular complications in patients with Chagas disease.<sup>6,7</sup>

Despite the significant progress made in recent years in the prevention, diagnosis, and treatment of Chagas disease, several challenges remain. Limited access to healthcare, particularly in rural and underserved areas, continues to hinder efforts to control the disease. Additionally, the lack of specific biomarkers for Chagas-related cardiovascular complications poses challenges for early diagnosis and management.<sup>7,8</sup>

Chagas disease remains a major public health challenge in endemic regions, with cardiovascular complications representing a significant burden of morbidity and mortality in affected individuals. Efforts to control the disease must focus on improving access to healthcare, implementing

effective vector control measures, and advancing research into new diagnostic and therapeutic approaches.<sup>7,8</sup>

### CLINICAL MANIFESTATIONS

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a complex multisystemic disorder that can affect various organs and systems, with the cardiovascular system being one of the most commonly involved. The clinical manifestations of Chagas-related cardiovascular diseases are diverse and can range from asymptomatic to severe and life-threatening.<sup>9,10</sup>

One of the hallmark features of Chagas-related cardiovascular disease is chronic Chagas cardiomyopathy, which affects approximately 20-30% of individuals with chronic Chagas disease. This condition is characterized by progressive myocardial damage, leading to left ventricular dilatation, systolic dysfunction, and heart failure. Patients with Chagas cardiomyopathy may present with symptoms such as dyspnea, fatigue, palpitations, and peripheral edema.<sup>9,10</sup>

Arrhythmias are another common manifestation of Chagas-related cardiovascular disease, affecting up to 30-50% of patients with chronic Chagas disease. These arrhythmias can range from benign premature ventricular contractions to more serious ventricular tachycardia and fibrillation, which can lead to sudden cardiac death. Conduction abnormalities, such as right bundle branch block and left anterior fascicular block, are also commonly seen in patients with Chagas disease.<sup>9,10</sup> Thromboembolic events are a significant complication of Chagas-related cardiovascular disease, particularly in patients with dilated cardiomyopathy. The presence of intracardiac thrombi, often associated with left ventricular aneurysms, can lead to embolic events, most commonly stroke. Patients with Chagas disease may also develop pulmonary embolism due to thrombus formation in the right heart chambers.<sup>9,10</sup>

In addition to these cardiovascular manifestations, Chagas disease can also affect the gastrointestinal system, leading to megaesophagus and megacolon, which can further complicate the clinical course of the disease. The presence of these gastrointestinal complications, along with cardiovascular involvement, can significantly impact the quality of life and prognosis of patients with Chagas disease.<sup>11</sup>

Chagas disease is a complex multisystemic disorder that can have profound effects on the cardiovascular system. The clinical manifestations of Chagas-related cardiovascular disease are diverse and can range from asymptomatic to severe and life-threatening. Early recognition and management of these manifestations are crucial for improving outcomes and reducing the burden of Chagas disease on affected individuals.<sup>11</sup>

### DIAGNOSIS

## The Interplay between Chagas Disease and Cardiovascular Disorders: A Comprehensive Review

The diagnosis of Chagas disease and its associated cardiovascular complications presents several challenges due to the diverse clinical manifestations of the disease and the lack of specific diagnostic tests. The diagnosis of Chagas disease is typically based on a combination of clinical findings, serological tests, and parasitological methods.<sup>11</sup>

In the acute phase of Chagas disease, diagnosis is often made through the detection of the parasite in peripheral blood using direct microscopic examination or polymerase chain reaction (PCR) techniques. However, as the acute phase is usually asymptomatic or mild, diagnosis is often missed, and the disease progresses to the chronic phase.<sup>12</sup>

In the chronic phase of Chagas disease, serological tests are the mainstay of diagnosis. These tests detect antibodies against *T. cruzi* antigens and include indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and immunochromatographic tests. While these tests are highly sensitive, they cannot differentiate between past and current infections, nor can they determine the presence of cardiac involvement.<sup>13</sup>

To assess cardiac involvement in Chagas disease, additional diagnostic tests are required. Electrocardiography (ECG) is often used to detect conduction abnormalities and arrhythmias, which are common in patients with Chagas-related cardiomyopathy. Echocardiography is also essential for evaluating cardiac structure and function, including left ventricular dilatation, wall motion abnormalities, and the presence of intracardiac thrombi.<sup>13</sup>

In recent years, advanced imaging techniques such as cardiac magnetic resonance imaging (MRI) and computed tomography (CT) have emerged as valuable tools for assessing cardiac involvement in Chagas disease. Cardiac MRI, in particular, allows for detailed evaluation of myocardial fibrosis, which is a hallmark feature of Chagas-related cardiomyopathy.<sup>13</sup>

Despite these advances, the diagnosis of Chagas-related cardiovascular complications remains challenging. The overlap of symptoms with other cardiovascular diseases, limited access to healthcare in endemic regions, and the lack of specific biomarkers for cardiac involvement pose significant diagnostic hurdles. Furthermore, the asymptomatic nature of Chagas-related cardiomyopathy in its early stages often delays diagnosis until the disease has progressed to a more advanced stage.<sup>14</sup>

The diagnosis of Chagas disease and its associated cardiovascular complications requires a multidisciplinary approach involving clinical, serological, and imaging modalities. Advances in diagnostic techniques have improved our understanding of the disease, but challenges remain in ensuring timely and accurate diagnosis, particularly in resource-limited settings.<sup>14</sup>

### DIAGNOSIS

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a complex disease with diverse clinical

manifestations, including potentially life-threatening cardiovascular complications. The diagnosis of Chagas disease and its associated cardiovascular disorders requires a multifaceted approach that combines clinical evaluation, serological testing, imaging studies, and, in some cases, molecular techniques.<sup>14</sup>

In the acute phase of Chagas disease, diagnosis is challenging due to the nonspecific nature of symptoms, which can include fever, malaise, and swelling at the site of infection (chagoma). Direct parasitological methods, such as microscopic examination of blood smears or PCR, can be used to detect the presence of the parasite in blood samples. However, these methods are most effective during the acute phase when parasite levels are highest and may be less reliable in the chronic phase of the disease.<sup>14</sup>

Serological tests are the mainstay of diagnosis for chronic Chagas disease. These tests detect antibodies against *T. cruzi* antigens and include indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and immunochromatographic tests. While these tests are highly sensitive, they cannot differentiate between past and current infections or determine the presence of cardiac involvement.<sup>14</sup>

To assess cardiac involvement in Chagas disease, additional diagnostic tests are required. Electrocardiography (ECG) is often used to detect conduction abnormalities and arrhythmias, which are common in patients with Chagas-related cardiomyopathy. Echocardiography is also essential for evaluating cardiac structure and function, including left ventricular dilatation, wall motion abnormalities, and the presence of intracardiac thrombi.<sup>14</sup>

Advanced imaging techniques, such as cardiac magnetic resonance imaging (MRI) and computed tomography (CT), are increasingly being used to assess cardiac involvement in Chagas disease. Cardiac MRI, in particular, allows for detailed evaluation of myocardial fibrosis, which is a hallmark feature of Chagas-related cardiomyopathy.<sup>15</sup>

The diagnosis of Chagas disease and its associated cardiovascular disorders requires a comprehensive approach that integrates clinical, serological, and imaging modalities. While significant progress has been made in the development of diagnostic tools for Chagas disease, challenges remain in ensuring timely and accurate diagnosis, particularly in resource-limited settings. Continued research into new diagnostic techniques and strategies is essential for improving the management and outcomes of patients with Chagas disease and its associated cardiovascular complications.<sup>16</sup>

### CONCLUSION

In conclusion, the relationship between Chagas disease and cardiovascular diseases is complex and multifaceted, with significant implications for both individual patients and public health. Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is endemic in Latin America and affects millions of people worldwide. While traditionally

## The Interplay between Chagas Disease and Cardiovascular Disorders: A Comprehensive Review

known for its acute and chronic manifestations, recent research has increasingly highlighted its association with cardiovascular complications, including cardiomyopathy, arrhythmias, and thromboembolic events.

The pathogenesis of Chagas-related cardiovascular diseases is multifactorial, involving parasite-induced myocardial damage, inflammatory responses, autonomic dysfunction, and microvascular abnormalities. These mechanisms contribute to the development of progressive myocardial dysfunction, arrhythmias, and thromboembolic events, which are the leading causes of morbidity and mortality in patients with Chagas disease.

Diagnosing and managing Chagas-related cardiovascular diseases present several challenges due to the diverse clinical manifestations of the disease and the lack of specific diagnostic tests. Current diagnostic approaches rely on a combination of clinical evaluation, serological testing, and imaging studies, but early detection and management of cardiovascular complications remain crucial for improving outcomes and reducing the burden of Chagas disease on affected individuals.

Moving forward, further research is needed to better understand the pathophysiology of Chagas-related cardiovascular diseases and to develop more effective diagnostic and therapeutic strategies. Additionally, efforts to improve access to healthcare in endemic regions and to implement integrated care approaches for affected individuals are essential for reducing the impact of Chagas disease on global cardiovascular health.

Chagas disease represents a significant public health challenge with profound cardiovascular implications. A comprehensive and multidisciplinary approach is necessary to address the complex interplay between Chagas disease and cardiovascular diseases, with the ultimate goal of improving outcomes and reducing the burden of disease on affected individuals and healthcare systems.

### REFERENCES

- I. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. *Int J Cardiol.* 2001;80:213–9. doi: 10.1016/S0167-5273(01)00497-1.
- II. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. *Nat Rev Cardiol.* 2012;9:576–89. doi: 10.1038/nrcardio.2012.109.
- III. Bocchi EA, Arias A, Verdejo H et al. The reality of heart failure in Latin America. *J Am Coll Cardiol.* 2013;62:949–58. doi: 10.1016/j.jacc.2013.06.013.
- IV. Traina MI, Sanchez DR, Hernandez S et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles, California. *Circ Heart Fail.* 2015;8:938–43. doi: 10.1161/CIRCHEARTFAILURE.115.002229.
- V. Bocchi EA. Heart failure in South America. *Curr Cardiol Rev.* 2013;9:147–56. doi: 10.2174/1573403X11309020007.
- VI. Stanaway JD, Roth G. The burden of Chagas disease: estimates and challenges. *Glob Heart.* 2015;10:139–44. doi: 10.1016/j.gheart.2015.06.001.
- VII. Tanowitz HB, Machado FS, Spray DC et al. Developments in the management of Chagas cardiomyopathy. *Expert Rev Cardiovasc Ther.* 2015;13:1393–409. doi: 10.1586/14779072.2015.1103648.
- VIII. Bern C. Chagas' disease. *N Engl J Med.* 2015;373:456–66. doi: 10.1056/NEJMra1410150.
- IX. Shen L, Ramires F, Martinez F et al. contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. *Circ Heart Fail.* 2017;10:e004361. doi: 10.1056/NEJMra1410150.
- X. Ramires FJA, Martinez F, Gomez EA et al. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy. *ESC Heart Fail.* 2018;5: 1069–71. doi: 10.1002/ehf2.12355.
- XI. Pan American Health Organization. General Information – Chagas Disease. 2011. [https://www.paho.org/hq/index.php?option=com\\_content&view=article&id=5856:2011-informacion-general-enfermedad-chagas&Itemid=0&lang=en](https://www.paho.org/hq/index.php?option=com_content&view=article&id=5856:2011-informacion-general-enfermedad-chagas&Itemid=0&lang=en) Available at. 12. WHO, Geneva: 2002.. WHO. TDR Strategic Directions: Chagas Disease
- XII. WHO. Control of Chagas disease : report of a WHO expert committee [meeting held in Buenos Aires from 16 to 20 October 1989] <https://apps.who.int/iris/handle/10665/37686>
- XIII. Jörg M, Storino R. Consensus on Chagas disease: Chagas disease in the 21st century. Consensus on an unfinished subject. *Revista Argentina de Cardiología.* 2002;70(Suppl 1):9–10.
- XIV. Barbosa MP, Carmo AA, Rocha MO, Ribeiro AL. Ventricular arrhythmias in Chagas disease. *Rev Soc Bras Med Trop.* 2015;48:4–10. doi: 10.1590/0037-8682-0003-2014.
- XV. Anselmi A, Moleiro F, Mendoza I. Clinical picture of Chagas disease. Differential diagnosis with dilated or congestive cardiomyopathy. *Revista Latina Cardiología.* 1982;3:97–104.